What's Happening?
Alida Biosciences has announced the launch of its EpiPlex Tri-Mod Service, which enables simultaneous detection and quantification of three key mRNA modifications: N6-methyladenosine (m6A), inosine, and pseudouridine. This service expands the EpiPlex platform,
providing a multidimensional view of RNA regulation that extends beyond traditional sequencing approaches. The service uses proprietary enzyme-driven chemistry to convert pseudouridine into a sequencing-readable signal, overcoming limitations of existing methods. This advancement allows researchers to study RNA modifications in lowly expressed transcripts, offering insights into RNA-level regulation and its role in disease biology.
Why It's Important?
The launch of the EpiPlex Tri-Mod Service is crucial for advancing the understanding of RNA modifications, which are central to cellular processes relevant to human disease. By providing a real-time readout of cell state, this service bridges the gap between molecular biology and clinical outcomes, offering new insights into immune activation, metabolic stress, and oncogenic signaling. The ability to study multiple RNA modifications together opens new avenues for research, potentially leading to breakthroughs in understanding disease mechanisms and developing targeted therapies. This service enhances the toolkit available to translational researchers, enabling large-scale studies that can inform AI-driven models and deepen biological understanding.
